On February 27, 2019, New York Genome Center (NYGC) Scientific Director and CEO Tom Maniatis, PhD, moderated a “NYGC Research Spotlight: The Future of Genomics” event for the MIT Enterprise Forum’s New York chapter, with presentations by NYGC Core Faculty Members Dan Landau, MD, PhD, and Neville Sanjana, PhD, and NYGC staff scientists Nicolas Robine, […]
NEW YORK, NY (August 8, 2018) — “A genome-wide net to catch and understand cancer,” is the title of the prize-winning essay written by NYGC Core Faculty Member Neville Sanjana, PhD, describing his research focused on pioneering gene-editing technology CRISPR, and now showcased as the August 8 cover story of Science Translational Medicine. Earlier this […]
Improving liquid biopsy, the emerging science which allows for early detection of cancer through the measurement of tumor DNA in a patient’s blood, is a key focus of the research team led by NYGC Core Faculty Member Dan Landau, MD, PhD, who holds a joint appointment as Assistant Professor of Medicine in the Division of […]
First Finnish genomic researcher to receive award honoring one of Finland’s most renowned scientists Tuuli Lappalainen, PhD, Core Faculty Member, New York Genome Center (NYGC) and Assistant Professor, Department of Systems Biology, Columbia University, is the recipient of the 2018 Leena Peltonen Prize for Excellence in Human Genetics. The award was presented to Dr. Lappalainen […]
A collaborative study between scientists at Memorial Sloan Kettering Cancer Center and the New York Genome Center has identified one way that lung cancer cells outsmart a common targeted drug therapy. The results, reported June 6, 2018 in the Proceedings of the National Academy of Sciences, pave the way for improved treatments. Read the June […]
Organoid profiling personalizes treatments for pancreatic cancer They could be used to select the treatments most likely to work in specific patients Patient-derived organoids, hollow spheres of cells cultured from tumors, can quickly and accurately predict how patients with pancreatic cancer respond to a variety of treatments, facilitating a precision-medicine approach to the deadly disease. […]
